Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05271968
Other study ID # APHP210864
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date April 2022
Est. completion date June 2022

Study information

Verified date February 2022
Source Assistance Publique - Hôpitaux de Paris
Contact Bacha Kaoutar
Phone (0)676089262
Email bacha.kaoutar@aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Scabies is a parasitic pathology contracted mainly through human contamination. It is caused by a parasite (Sarcoptes Scabiei var. hominis) which lodges into the top layer of the epidermis creating a burrow, which can measure 5 mm to 15 mm, where the female lays her eggs. After 4-6 weeks the patient develops an allergic reaction to the presence of mite proteins and feces in the scabies burrow, causing intense itch and rash. The usual adult form, called common scabies, is characterized by this nocturnal pruritus, and typical and/or atypical lesions. The typical lesions are the vesicle (translucent vesicle on an erythematous base), the scabious burrow (due to the tunnel dug by the female in the stratum), and the papulo- nodule -nodular scabious (red/brown infiltrated on palpation, predominantly on the male genital areas). They predominate in certain regions: the interdigital region of the hands, the anterior face of the wrists, the external face of the elbows, the axillary region, the areolas, the nipples, the umbilical region, the male external genitalia, the buttock region, the face inner thighs. Scabies occurs worldwide. However, studies have shown a greater prevalence among populations that do not have access to common hygiene measures: poor, young children and elderly in resource -poor communities, migrant, homeless populations, etc. The "Baudelaire outpatient clinic" (BOPC) at St Antoine hospital in Paris offers general medicine consultations. It has the particularity of offering a so called "Permanent d'Accès Aux Soins" service that allowed any person without health assurance to have access to a general practitioner and treatment, free of charge and help to recover its social rights. Consequently, more than 60% of the patients encountered at the consultation of the BOPC are in a precarious situation. Usually, poor patients with scabies may be offered a shower and clean clothes at the BOPC Therefore it seemed to us the ideal place to evaluate a treatment's scabies in this population including the hygiene treatment.


Description:

The objective of our study is to evaluate the superiority of a global management of scabies compared to a conventional treatment. The classic treatment recommended is the prescription of an oral drug, Ivermectin to be taken two times at one or 2 weeks interval. And recommendations on the need to change the clothes and the linen of the bedding the following day after taking the drug, washing them at more than 50° as well as all the clothes three days before are explained. The first course of oral treatment is swallowed at the BOPC, while the second course is given to be swallowed one week later. For the interventional arm, the first course of the oral treatment has also to be swallowed at the BOPC but the patient will have to come back the following day to take a shower at the BOPC and will receive new clothes. The second course will be given, but the patient will have to come back the following day of the second course to take a shower at the BOPC and to receive again new clothes. We will compare the number of patients cured in the interventional arm versus the control arm at D28.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 218
Est. completion date June 2022
Est. primary completion date April 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient seen in consultation at the outpatient clinic, diagnosed with non-hyperkeratotic scabies. - Living on the streets or without access to body care. - Having received information on the protocol and having signed consent Exclusion Criteria : - Patient alcoholic on the day of the consultation - Medical history fo psychiatric disease , severe somatic comorbidity, allergy to Ivermectin, pregnant woman - Patient not understanding the on-site management (shower, change of clothes, taking the first dose of the drug on site) - Non-communicating patient - Hyperkeratotic or impetiginized scabies - Patients not reachable by phone - Patient having been treated for scabies less than 45 days before - Patients under guardianship / curator ship or adults and subject to another protective measure. - Pregnant and breastfeeding women - Persons deprived of liberty by judicial and administrative decision

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Global management of scabies
For the interventional arm, the first course of the oral treatment has also to be swallowed at the BOPC service, but the patient will have to come back the following day to take a shower at the BOPC service and will receive new clothes. The second course will be given, but the patient will have to come back the following day of the second course to take a shower at the BOPC service and to receive again new clothes

Locations

Country Name City State
France Hopital Saint Antoine - Polyclinique Beaudelaire Paris Ap-hp

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Healing To assess the impact on the scabies healing rate by providing to patient in precarious situation a shower and clean clothes, twice at one-week intervals, versus the standard hygiene recommendations given to patients.
Number of patients cured in the interventional arm (P=Policlinic) versus the control arm (D=home) at D28.
28 days
Secondary Compliance Compliance with treatment and effectiveness of the proposed device: determination of the number of patients seen again on D2 and D8 for the shower, and on D28 for the two groups. 28 days
Secondary Validity of the proposed clinical criteria Validity of the proposed clinical criteria: the cure rate in each group will be analyzed according to the three clinical grades, confirmed, probable and possible 28 days
See also
  Status Clinical Trial Phase
Completed NCT02572986 - A Study to Evaluate the Therapeutic Equivalence of Generic Permethrin Cream 5% to Elimite® in the Treatment of Scabies Phase 3
Completed NCT00884728 - Evaluation of a Regional Healthy Skin Program in Remote Aboriginal Communities of Australia's Northern Territory N/A
Completed NCT05025696 - Efficacy and Side Effects of Blacksoap® as Adjuvant Therapy of Scabies N/A
Completed NCT04205669 - Comparing the Effectiveness of Individual vs. Household Treatment for Scabies in Lambaréné, Gabon Phase 4
Completed NCT02254564 - PCR (Polymerase Chain Reaction) Assay for Diagnosis of Sarcoptes Scabiei
Not yet recruiting NCT06404333 - Evaluating Pediatric Ivermectin in Children Under 15 kg (EPIC-15) Phase 2
Completed NCT03676140 - Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs ) Phase 3
Recruiting NCT05875441 - Efficacy and Safety Study of Moxidectin in Adults With Scabies Phase 2
Completed NCT02978508 - Bio-equivalence Study Comparing Permethrin Cream, 5% With Elimite in Patients With Active Scabies. Phase 3
Recruiting NCT04332068 - Ivermectin Safety in Small Children Phase 2
Recruiting NCT04844905 - Adjunctive Ivermectin Mass Drug Administration for Malaria Control Phase 3
Not yet recruiting NCT06380452 - Therapy for Scabies With Two Differently Concentrated Permethrin Creams Phase 3
Completed NCT00604084 - Veron Scabies Education and Eradication Program N/A
Completed NCT02485717 - Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies Phase 3
Completed NCT02485704 - Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies Phase 3
Recruiting NCT05310734 - PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age With Scabies Phase 4
Recruiting NCT04931680 - Risk Factors for Treatment Failure of Scabies in Autochthonous Populations of French Guiana (GUYAGALE)
Completed NCT06396507 - Sulfur vs. Different Regimes of Permethrin for Scabies Phase 3
Completed NCT05862701 - Comparison of Topical 5% Permethrin and Topical 10% Sulfur in the Treatment of Scabies Phase 1
Not yet recruiting NCT05500326 - Ivermectin Therapy for Scabies Infection in Children Younger Than 5 Years of Age (ITCHY Study) Phase 2